A case of Stevens-Johnson syndrome associated with oxaprozin therapy.
We describe a case of Stevens-Johnson syndrome (SJS) associated with oxaprozin ("Daypro"), a relatively new nonsteroidal antiinflammatory drug (NSAID) of the propionic acid group. Our literature review shows that among the NSAID associated with SJS, oxicams have the highest risk. The risk is low for the propionic acid group. Indeed, the prevalence of their use was too low to permit an analysis of individual drugs. This is the first reported case of SJS associated with oxaprozin. Although the patient we describe survived the reaction, we think it is important to report such a potentially fatal reaction to a relatively newly available medication.
Department of Medicine, Sunnybrook Health Science Centre, University of Toronto, Ontario, Canada.
M J
MJ
Bell
L D
LD
Bishara
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D000077431:Oxaprozin; D011422:Propionates / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000175:diagnosis
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011422:Propionates; D000077431:Oxaprozin